Panic Disorder
📧 Sign up to get email alerts when something new happens for Panic Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-11-23FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Marlex Pharmaceuticals, Inc.)
FDA approved a generic venlafaxine hydrochloride product from Marlex Pharmaceuticals, marking the first original ANDA approval for this gene…
-
FDA approval · 2018-11-21FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA granted approval for the original application of a generic fluoxetine hydrochloride product.
-
FDA approval · 2018-11-21FDA Approved: VENLAFAXINE — Original Application (Cadila Pharmaceuticals Limited)
FDA approved the original generic application for venlafaxine from Cadila Pharmaceuticals Limited.
-
FDA label_change · 2018-08-13FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for venlafaxine hydrochloride filed by Macleods Pharmaceuticals Limited. The approval is associated …
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Exposure Therapy For Veterans With PTSD And Panic Attacks [NA]
A completed clinical trial investigating exposure therapy for veterans with PTSD and panic attacks; results were posted in 2018.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-06-12FDA Approved: PAROXETINE — Original Application (Rhodes Pharmaceuticals L.P.)
FDA approved the original abbreviated new drug application for paroxetine hydrochloride hemihydrate from Rhodes Pharmaceuticals, establishin…
-
FDA approval · 2018-05-08FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
The FDA approves Accord Healthcare, Inc.'s supplemental application for sertraline hydrochloride (sertraline HCl).
-
CLINICAL_TRIALS trial_result · 2018-05-03Clinical Trial Update: D-cycloserine Augmented CBT for Panic Disorder [Phase 3]
A Phase 3 trial evaluating D-cycloserine as an adjunct to cognitive-behavioral therapy for Panic Disorder was terminated.
-
CLINICAL_TRIALS research · 2018-04-27Clinical Trial Update: Rumination Focus Cognitive Behavior Therapy [NA]
Clinical trial update on Rumination Focus Cognitive Behavior Therapy for depression and anxiety disorders. The current status is unknown.
-
CLINICAL_TRIALS research · 2018-04-13Clinical Trial Update: Neuroimaging of Pavlovian Fear Conditioning Processes in Patients With Pathological Anxiety [NA]
An imaging study is investigating fear conditioning processes in patients with pathological anxiety, including PTSD and related disorders; t…
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders [Phase 4]
Phase 4 trial of sertraline for social phobia with co-occurring anxiety and mood disorders has been terminated. The study examined sertralin…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder [Phase 2]
Phase 2 clinical trial in panic disorder evaluated exposure-based therapy with D-Cycloserine enhancement and genetic modulators; results hav…
-
CLINICAL_TRIALS trial_result · 2018-02-06Clinical Trial Update: Using the Canary Breathing System for Panic Disorder Patients [NA]
Clinical trial update for panic disorder using the Canary Breathing System; study completed with results posted in 2018.
-
FDA approval · 2017-12-19FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) submitted by Viatris Specialty LLC.
-
FDA approval · 2017-12-19FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Vertical Pharmaceuticals, LLC.
-
FDA approval · 2017-12-08FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for sertraline hydrochloride submitted by Mylan Pharmaceuticals, likely affecting the product la…
-
FDA approval · 2017-11-20FDA Approved: FLUOXETINE — Original Application (NIVAGEN PHARMACEUTICALS, INC.)
FDA approved NIVAGEN Pharmaceuticals' original application for fluoxetine hydrochloride, granting marketing approval for a generic version o…
-
FDA approval · 2017-11-16FDA Approved: FLUOXETINE — Original Application (Endo USA, Inc.)
FDA approves Endo USA, Inc.'s original application for a generic fluoxetine product.
-
FDA approval · 2017-10-05FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approves Macleods Pharmaceuticals Limited's venlafaxine hydrochloride original application (generic), expanding access to treatment for …
-
CLINICAL_TRIALS trial_result · 2017-09-15Clinical Trial Update: Levetiracetam for the Treatment of Alcohol Dependence and Anxiety [Phase 2]
Phase 2 trial update for levetiracetam in treating alcohol dependence and anxiety disorders; results completed with posted results in 2017.
-
FDA approval · 2017-08-18FDA Approved: PAROXETINE — Original Application (Solco Healthcare LLC)
FDA approves the original generic application for Paroxetine (Solco Healthcare LLC).
-
CLINICAL_TRIALS trial_result · 2017-08-16Clinical Trial Update: Neural Effects of Cognitive-behaviour Therapy in Panic Disorder [NA]
The clinical trial examining neural effects of cognitive-behavioral therapy for panic disorder has completed.
-
FDA approval · 2017-08-03FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Sertraline Hydrochloride submitted by Rising Pharma Holdings, Inc.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Neurobiological Mechanisms in Panic Disorder
This completed clinical trial update from the National Institute of Mental Health reports on neurobiological mechanisms involved in panic di…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ [Phase 1]
Phase 1 study evaluating substance P neurotransmission in panic disorder using PET imaging of NK1 receptors with the radiotracer [18F]SPA-RQ…